Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET

Company Participants

Robert Shawah - Co-Founder & CFO
David Luci - Co-Founder, President, CEO, Corporate Secretary & Director

Conference Call Participants

Thomas Yip - H.C. Wainwright
John Stinson - Private Investor

Operator

Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third Quarter 2024 Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Robert Shawah, Chief Financial Officer. Thank you. You may begin.

Robert Shawah

Thank you. Good morning, and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the third quarter of 2024, which is available on our website at acurxpharma.com.

Joining me today is Dave Luci, President and CEO of Acurx, who will give a corporate update and outlook. After that, I'll provide some highlights of the financials for the quarter ended September 30, 2024, and then turn the call back over to Dave for his closing remarks.

As a reminder, during today's call, we'll be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions, estimates and projections about future events, that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

Investors should consider these risks and other information described in our filings made with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, which we filed on Tuesday, November 12, 2024.

We request not to place undue reliance on these forward-looking statements, and Acurx disclaims any obligation to update such statements at any time in the future. This conference call contains time-sensitive information that's accurate only as of the date of this live broadcast today, November 13, 2024.

I'll now turn the call over to Dave. Dave?

David Luci

Thanks, Rob. Good morning, everyone, and thanks for joining us to review our financial results for the third quarter of 2024, and also to hear some very exciting recent updates. Then we'd be pleased to take any questions. First, I'll summarize some of our key activities for the third quarter of '24 or in some cases, shortly thereafter.

In July, results from the ibezapolstat Phase II clinical trial in patients with C. diff infection were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn Eubank, PharmD, Research Assistant Professor at the University of Houston College of Pharmacy. Taryn delivered an oral presentation entitled: "clinical efficacy of ibezapolstat in CDI: results from Phase II trials."